• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Horizon

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · September 6, 2011

Horizon Pharma Receives U.S. Patent Allowance for DUEXIS(R) (Ibuprofen/Famotidine)

NORTHBROOK, IL -- (MARKET WIRE) -- 09/06/11 -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial …

News · July 28, 2011

Horizon Pharma Announces Pricing of its Initial Public Offering

NORTHBROOK, IL. – July 28, 2011 – Horizon Pharma, Inc. (Nasdaq: HZNP) today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a price to the public of $9.00 …

News · April 25, 2011

Horizon Pharma Announces FDA Approval of DUEXIS®(ibuprofen/famotidine) for the Relief of the Signs and Symptoms of Rheumatoid Arthritis and Osteoarthritis and to Decrease the Risk of Developing Upper Gastrointestinal Ulcers

NORTHBROOK, Ill. – April 25, 2011 – Horizon Pharma, Inc., a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact